Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

2.500 +0.370 (+17.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CytomX Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
CytomX Therapeutics (NASDAQ: CTMX) and Regeneron (NASDAQ: REGN) Enter into Strategic Collaboration to Develop Bispecific Therapies to Treat Cancer
CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company, which is focused on developing innovative treatments for a wide-range 
Via Spotlight Growth
CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron
Via Benzinga
Recap: CytomX Therapeutics Q2 Earnings
CytomX Therapeutics (NASDAQ:CTMX) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:15 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Mullen (MULN) Stock Pops 4% on ELMS Funding News
Mullen (MULN) stock is on the move Thursday following news of the EV company acquiring funding for its purchase of ELMS assets. 
Via InvestorPlace
CytomX Therapeutics Cuts Workforce, Extend Cash Runway Into 2025
Via Benzinga
Analyst Ratings for CytomX Therapeutics
Analysts have provided the following ratings for CytomX Therapeutics (NASDAQ:CTMX) within the last quarter: 
Via Benzinga
Why Is CytomX Therapeutics (CTMX) Stock Up 29% Today?
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN). 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session
Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! It's time to start off the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
Via InvestorPlace
Why DWAC Is Trading Lower By Around 19%; Here Are 32 Stocks Moving Premarket
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares rose 39.6% to $4.44 in pre-market trading after gaining 7% on Friday. 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping 250 points following the release of data on initial jobless claims. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 49 companies set new 52-week lows. 
Via Benzinga
Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue
U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims. 
Via Benzinga
What To Know About Mizuho's Downgrade of CytomX Therapeutics
Mizuho downgraded its rating of CytomX Therapeutics (NASDAQ:CTMX) to Neutral with a price target of $4.00, changing its price target from $16.00 to $4.00. Shares of CytomX Therapeutics are trading down... 
Via Benzinga
This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session
Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
This Analyst Cuts Price Target On Microsoft; Here's The Biggest Price Target Changes For Thursday
Truist Securities cut Criteo S.A. (NASDAQ: CRTO) price target from $40 to $35. Criteo shares fell 3.5% to close at $22.92 on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.